舒尼替尼与索拉非尼治疗晚期肝细胞癌的效果比较

高斌成; 郭卉; 孙乐; 周洁; 蒋冬梅

doi:10.3969/j.issn.1001-5256.2018.08.19

舒尼替尼与索拉非尼治疗晚期肝细胞癌的效果比较

DOI: 10.3969/j.issn.1001-5256.2018.08.19

1. 长安医院肿瘤科
2. 西安交通大学第一附属医院肿瘤内科

基金项目:

国家自然科学基金(81672432)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2576
- HTML全文浏览量: 43
- PDF下载量: 430
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-08
- 出版日期: 2018-08-20

Clinical effect of two targeted drugs in treatment of advanced hepatocellular carcinoma: A comparative analysis

Department of Oncology, Chang'an Hospital

Research funding:

摘要

摘要: 目的探究靶向药物舒尼替尼应用于晚期肝细胞癌（HCC）治疗的临床疗效。方法将2015年9月-2016年9月长安医院收治的48例晚期HCC患者纳入研究,按照治疗药物的不同分为对照组和观察组,每组24例。对照组患者口服索拉非尼治疗,观察组口服舒尼替尼治疗。随访观察1年后,记录两组患者的临床疗效、临床症状改善以及不良反应情况。计量资料组间比较采用t检验,计数资料组间比较采用Mann-Whitney U检验。结果观察组的疾病控制率为68.42%（13/19）,其中有效缓解4例,病情控制稳定9例;对照组的疾病控制率为76.19%（16/21）,两组的疾病控制率差异无统计学意义（P>0.05）。对照组手足皮肤反应发生率为12.5%,观察组为0,两组比较差异有统计学意义（U=31.07,P<0.05）。观察组中性粒细胞减少发生率为25%,明显高于对照组（16.67%）（U=29.87,P<0.05）。两组均出现消化道反应如恶心、呕吐等以及肝功能异常,因患者胃肠道反应可耐受未进行处理,肝功能异常患者给予保肝药物等处理,均得到有效缓解。结论舒尼替尼在治疗晚期HCC中有良好的临床效果,需要...
- 癌,肝细胞 /
- 索拉非尼 /
- 舒尼替尼 /
- 治疗结果
Abstract: Objective To investigate the clinical effect of the targeted drug sunitinib in the treatment of advanced hepatocellular carcinoma ( HCC) . Methods A total of 48 patients with advanced HCC who were admitted to Chang'an Hospital form September 2015 to September2016 were enrolled and divided into control group and observation group, with 24 patients in each group. The patients in the control group were given oral sorafenib, and those in the observation group were given oral sunitinib. The patients were followed up for 1 year, and the clinical outcome, improvement in clinical symptoms, and adverse events were recorded. The t-test was used for comparison of continuous data between groups, and the Mann-Whitney U test was used for comparison of categorical data between groups. Results The disease control rate ( DCR) in the observation group was 68. 42% ( 13/19) , and among these 13 patients, 4 achieved effective remission and 9 had stable disease; the DCR in the control group was 76. 19%, and there was no significant difference in DCR between the two groups ( P > 0. 05) .There was a significant difference in the incidence rate of hand-foot skin reaction between the observation group and the control group ( 0%vs 12. 5%, U = 31. 07, P < 0. 05) . The observation group had a significantly higher incidence rate of neutropenia than the control group ( 25% vs 16. 67%, U = 29. 87, P < 0. 05) . Both groups experienced digestive tract reactions ( nausea and vomiting) and abnormal liver function; since the digestive tract reactions were tolerable, no special treatment was given, and the patients with abnormal liver function were given liver-protecting drugs, so all adverse events were effectively alleviated. Conclusion Sunitinib has a good clinical effect in the treatment of advanced HCC, and further studies with a larger sample size are needed to investigate the long-term clinical effect of sunitinib and combined treatment.
- carcinoma, hepatocellular /
- sorafenib /
- sunitinib /
- treatment outcome

HTML全文

参考文献(23)

[1]ZHANG Y, QU CF, REN JS, et al.Prevalence and death dataset of liver cancer in China[J].Chin J Oncol, 2015, 37 (9) :705-720. (in Chinese) 张玥, 曲春枫, 任建松, 等.中国肝癌发病与死亡数据集[J].中华肿瘤杂志, 2015, 37 (9) :705-720.

[2]YUAN G, HAN T, LIU ZZ, et al.Compound radix sophorae flavescentis combined with ensure nutrition on malnutrition of advanced liver cancer[J].Chin J Med Offic, 2017, 45 (9) :891-893. (in Chinese) 袁钢, 韩涛, 刘中正, 等.苦参联合安素治疗晚期肝癌营养不良效果观察[J].临床军医杂志, 2017, 45 (9) :891-893.

[3]LIU XH, ZHAO YM, ZHAO XF, et al.Diagnostic and therapeutic progress on hepatocellular carcinoma[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (2) :20-25. (in Chinese) 刘秀红, 赵一鸣, 赵晓飞, 等.肝细胞癌诊断与治疗研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (2) :20-25.

[4]ZHANG CY, ZHAO XX, LU ZM, et al.Research advances in sorafenib-induced apoptotic signaling pathways in liver cancer cells[J].J Clin Hepatol, 2016, 32 (4) :816-820. (in Chinese) 张朝亚, 赵相轩, 卢再鸣, 等.索拉非尼诱导肝癌细胞凋亡信号通路的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :816-820.

[5]SUN H, HAN WJ.Analysis of Sola Fini for primary liver cancer[J].Pract J Cancer, 2014, 29 (4) :442-444. (in Chinese) 孙恒, 韩文杰.索拉非尼对原发性肝癌患者疗效的研究分析[J].实用癌症杂志, 2014, 29 (4) :442-444.

[6]MA GA.Clinical effect of sorafenib in treatment of advanced hepatocellular carcinoma[J].J Clin Res, 2016, 33 (5) :986-988. (in Chinese) 马国安.索拉非尼治疗中晚期肝细胞癌的临床疗效分析[J].医学临床研究, 2016, 33 (5) :986-988.

[7]YU L, LIN LZ.Clinical effect of traditional Chinese medicine combined with sunitinib in treatment of advanced liver cancer:A case report[J].Chin J Integr Trad West Med, 2014, 34 (6) :758-759. (in Chinese) 余玲, 林丽珠.中医药联合舒尼替尼治疗晚期肝癌1例[J].中国中西医结合杂志, 2014, 34 (6) :758-759.

[8]YANG XN, WU YL.RECIST-New guidelines to evaluate the response to treatment in solid tumors[J].J Evid-based Med, 2004, 4 (2) :85-90. (in Chinese) 杨学宁, 吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学, 2004, 4 (2) :85-90.

[9]GU CY.New criteria for drug toxicity:National Cancer InstituteCommon Toxicity Criteria version 2.0[J].Progr Japanese Med, 2001, 22 (11) :483-486. (in Chinese) 谷昌彦.新的药物毒副反应判定标准:NCI——CTC2.0版本[J].日本医学介绍, 2001, 22 (11) :483-486.

[10]SHAO JS, LU HZ, ZHANG YX.Research advances in epidemiology of hepatocellular carcinoma[J].Chin Hepatol, 2011, 16 (6) :503-505. (in Chinese) 邵家胜, 卢洪洲, 张永信.肝细胞癌流行病学研究进展[J].肝脏, 2011, 16 (6) :503-505.

[11]WAN J, TANG CX, FENG B, et al.Expressions of Numb and VEGF in hepatocellular carcinoma and the clinical significance[J].Chin J Gen Sur, 2015, 24 (1) :39-44. (in Chinese) 万健, 唐才喜, 冯斌, 等.原发性肝癌中Numb和VEGF的表达及临床意义[J].中国普通外科杂志, 2015, 24 (1) :39-44.

[12]MA Q, XIE SL, WANG GY, et al.Influence of lentiviral-mediated P27RF-Rho gene silence in invasion of liver cancer cells[J].J Jilin Univ:Med Edit, 2016, 42 (2) :260-265. (in Chinese) 马强, 谢淑丽, 王广义, 等.慢病毒介导靶向P27RF-Rho基因沉默对肝癌细胞侵袭性的影响[J].吉林大学学报:医学版, 2016, 42 (2) :260-265.

[13]GUO ZY, HUANG FZ.Targeted therapy for hepatocellular carcinoma at intermediate and advanced stage:Difficulties and hope[J].Chin J Gen Surg, 2017, 26 (1) :109-115. (in Chinese) 郭之野, 黄飞舟.中晚期肝细胞肝癌的靶向治疗:困境与希望[J].中国普通外科杂志, 2017, 26 (1) :109-115.

[14]LI SJ, YANG ZB.Research advances in the role of Wnt/β-catenin signaling pathway-related molecules in targeted therapy for liver cancer[J].Shandong Med, 2016, 56 (10) :99-101. (in Chinese) 李圣杰, 杨之斌.Wnt/β-catenin信号通路相关分子在肝癌靶向治疗中的研究进展[J].山东医药, 2016, 56 (10) :99-101.

[15]SHAO P, TANG SH, LIN X, et al.Research advances in vectors used in targeted gene therapy for liver cancer[J].Proce Clin Med, 2015, 24 (3) :211-214. (in Chinese) 邵平, 汤诗杭, 林翔, 等.肝癌靶向基因治疗载体研究进展[J].临床医药实践, 2015, 24 (3) :211-214.

[16]CHEN C.Wnt/β-catenin and TGF-βsignaling pathways and targeted therapy for liver cancer[J].Acta Acad Med Xuzhou, 2015, 35 (1) :67-70. (in Chinese) 陈聪.Wnt/β-catenin及TGF-β信号通路与肝癌的靶向治疗[J].徐州医学院学报, 2015, 35 (1) :67-70.

[17]RINI BI, ESCUDIER B, TOMCZAK P, et al.Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) :A randomised phase 3 trial[J].Lancet, 2016, 378 (9807) :1931-1939.

[18]YUAN HH, BAI YX, ZHANG TT, et al.Clinical observation on efficacy and adverse reactions of sorafenib in treating advanced hepatocellular carcinoma[J].China Oncol, 2012, 22 (1) :52-55. (in Chinese) 苑珩珩, 白玉贤, 张婷婷, 等.以索拉非尼为基础治疗晚期肝细胞癌的疗效和不良反应临床观察[J].中国癌症杂志, 2012, 22 (1) :52-55.

[19]ZHOU XP, ZHANG L.Progress in detection methods and clinical applications of serum alpha fetoprotein[J].Int Med China, 2015, 10 (2) :264-266. (in Chinese) 周晓萍, 张玲.血清甲胎蛋白检测方法及临床应用研究进展[J].内科, 2015, 10 (2) :264-266.

[20]UEDA T.Current status of molecular targeted therapy for hematologic malignancies:Introduction[J].Int J Clin Oncol, 2014, 19 (1) :1-2.

[21]Mc NAMARA MG, LE LW, HORGAN AM, et al.A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma[J].Cancer, 2015, 121 (10) :1620-1627.

[22]PARIKH ND, MARSHALL VD, SINGAL AG, et al.Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma:An analysis of the SEER-medicare database[J].Hepatology, 2017, 65 (1) :122-133.

[23]MIN D, BI J, LIU X, et al.Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a smallmolecule VEGFR-2 tyrosine kinase inhibitor apatinib:A case report[J].Medicine (Baltimore) , 2016, 95 (31) :e4368.

施引文献

资源附件(0)

访问统计